Artificial Intelligence May Discover the Next Blockbuster Drug
AI is revolutionizing countless industries, but its biggest impact may be felt in medicine. Machine learning has proved capable of identifying signs of disease in medical images and records, and it may become invaluable for analyzing vast genomic data sets for clues as to the origins of different disorders. Benevolent AI, headquartered in London, is working to apply the latest AI techniques to the identification and development of novel drug compounds. The company’s CEO, Ken Mulvaney, met with MIT Technology Review’s senior editor for AI, Will Knight, to discuss AI’s relevance to drug discovery and medicine, and to talk about his company’s ambitious plans.
Keep Reading
Most Popular

A quick guide to the most important AI law you’ve never heard of
The European Union is planning new legislation aimed at curbing the worst harms associated with artificial intelligence.

It will soon be easy for self-driving cars to hide in plain sight. We shouldn’t let them.
If they ever hit our roads for real, other drivers need to know exactly what they are.

This is the first image of the black hole at the center of our galaxy
The stunning image was made possible by linking eight existing radio observatories across the globe.

The gene-edited pig heart given to a dying patient was infected with a pig virus
The first transplant of a genetically-modified pig heart into a human may have ended prematurely because of a well-known—and avoidable—risk.
Stay connected

Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.